Isochoric Pressure Assisted Vitrification of Testicular Tissue and Whole Testes

等容压辅助睾丸组织和整个睾丸的玻璃化

基本信息

  • 批准号:
    9466962
  • 负责人:
  • 金额:
    $ 28.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-21 至 2019-03-31
  • 项目状态:
    已结题

项目摘要

This program aims to develop a novel method for cryopreserving human testicular tissue and whole testes, which can also be applied to ovarian tissue and gonadal preservation and ultimately any cells, tissues, and whole organs. This multi-pronged approach builds on recent advances in machine perfusion, nature-inspired cytoprotection strategies, and non-toxic cryoprotectant solutions, combining them with our novel method for constant-volume, pressure-assisted cooling. Our method promises to achieve vitrification of living tissues without the aid of toxic concentrations of cryoprotectants, in a system at thermodynamic equilibrium and potentially at temperatures as high as -80°C (capable of dry-ice shipment). It ameliorates or entirely circumvents many of the limitations of conventional cryopreservation methods for large tissues, including damaging ice crystallization, deleterious changes in solute concentrations, and volumetric changes. This approach has the potential to enable indefinite banking of testicular tissues, whole testes, and other living materials while dramatically limiting tissue injury currently associated with ex-vivo storage. The technical objective of this Phase 1 proposal is to develop an optimized cocktail and protocol for preservation and indefinite banking of testicular tissue. We will develop our method across three specific aims. Building upon preliminary studies that demonstrate the feasibility of isochoric preservation, in Aim 1 we will begin with extended feasibility studies focused on investigating the combined effects of temperature, pressure and CPA on testicular-cell viability following equilibrium ice-free isochoric preservation. Specifically, we will use semi- high-throughput screening to measure the viability of human Sertoli cells, Leydig cells and endothelial cells with targeted pressures of up to 160 MPa (pressure at which red-blood cells show improved cryopreservation). In parallel studies in Aim 2, we will use well established methods developed by our broader group to define new thermodynamic profiles for novel, nature-inspired cryoprotectant solutions in an isochoric (constant- volume) system; this will allow us to select solutions that allow for pressure-assisted vitrification of living materials at low to intermediate pressures and much higher storage temperatures than traditionally needed for ice-free cryopreservation. In Aim 3, we select the most effective cryoprotectant solutions established in Aim 1-2 to evaluate our “high sub-zero vitrification” in human testicular tissue strips and compare outcome with conventional state-of-the-art isobaric preservation. Tissue will be evaluated by measuring tissue-viability, as well as histology, immunohistochemistry and xenotransplantation into infertile nude mice. We will additionally test the augmentation of these methods with subnormothermic machine perfusion, enabling further reduction of ischemic tissue injury. Success of these novel approaches individually or in combination will likely enable breakthroughs in oncofertility and biopreservation research and clinical practice.
该计划旨在开发一种冷冻保存人类睾丸组织和整个睾丸的新方法,该方法也可应用于卵巢组织和性腺的保存,并最终用于任何细胞,组织和整个器官。这种多管齐下的方法建立在机器灌注,自然启发的细胞保护策略和无毒冷冻保护剂解决方案的最新进展的基础上,将它们与我们的恒定体积,压力辅助冷却的新方法相结合。我们的方法有望在热力学平衡和可能高达-80 ° C的温度下(能够干冰运输)的系统中,在没有有毒浓度的冷冻保护剂的帮助下实现活组织的玻璃化。它改善或完全避免了传统冷冻保存方法对大组织的许多限制,包括破坏性的冰结晶、溶质浓度的有害变化和体积变化。这种方法有可能实现睾丸组织、整个睾丸和其他活体材料的无限期储存,同时显著限制目前与离体储存相关的组织损伤。本1期提案的技术目标是开发一种优化的混合物和方案,用于睾丸组织的保存和无限期储存。我们将在三个具体目标上发展我们的方法。在初步研究的基础上,证明了等容保存的可行性,在目标1,我们将开始扩展的可行性研究,重点是调查温度,压力和CPA的睾丸细胞活力的综合影响后,平衡无冰等容保存。具体而言,我们将使用半高通量筛选来测量人支持细胞、间质细胞和内皮细胞的活力,目标压力高达160 MPa(红细胞显示出改善的冷冻保存的压力)。在目标2的平行研究中,我们将使用由我们更广泛的团队开发的成熟方法来定义等容环境中新型天然冷冻保护剂溶液的新热力学特征。定容系统;这将使我们能够选择允许在低到中等压力和比传统的冰所需的高得多的储存温度下对生物材料进行压力辅助玻璃化的解决方案,免费冷冻保存。在目标3中,我们选择了目标1-2中确定的最有效的冷冻保护剂溶液,以评估我们在人睾丸组织条中的“高度零下玻璃化”,并将结果与传统的最先进的等压保存进行比较。将通过测量组织活力以及组织学、免疫组织化学和异种移植到不育裸鼠中来评价组织。我们还将测试这些方法的增强与亚常温机器灌注,使进一步减少缺血性组织损伤。这些新方法单独或组合的成功可能会使肿瘤生育和生物保存研究和临床实践取得突破。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL John TAYLOR其他文献

MICHAEL John TAYLOR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL John TAYLOR', 18)}}的其他基金

Isochoric Pressure Based Preservation of Cells, Tissues and Organs
基于等容压的细胞、组织和器官保存
  • 批准号:
    9141809
  • 财政年份:
    2016
  • 资助金额:
    $ 28.51万
  • 项目类别:
Non-Enzymatic Cryogenic Isolation of Therapeutic Cells
治疗细胞的非酶低温分离
  • 批准号:
    8394427
  • 财政年份:
    2012
  • 资助金额:
    $ 28.51万
  • 项目类别:
Pancreas perfusion with PFC-Unisol
使用 PFC-Unisol 进行胰腺灌注
  • 批准号:
    8199010
  • 财政年份:
    2011
  • 资助金额:
    $ 28.51万
  • 项目类别:
New Solutions to Improve Islet Recovery after Machine Preservation of Pancreas
改善胰腺机器保存后胰岛恢复的新解决方案
  • 批准号:
    7924489
  • 财政年份:
    2007
  • 资助金额:
    $ 28.51万
  • 项目类别:
New Solutions to Improve Islet Recovery after Machine Preservation of Pancreas
改善胰腺机器保存后胰岛恢复的新解决方案
  • 批准号:
    7495575
  • 财政年份:
    2007
  • 资助金额:
    $ 28.51万
  • 项目类别:
New Solutions to Improve Islet Recovery after Machine Preservation of Pancreas
改善胰腺机器保存后胰岛恢复的新解决方案
  • 批准号:
    7328324
  • 财政年份:
    2007
  • 资助金额:
    $ 28.51万
  • 项目类别:
New Solutions Islet Recovery Preservation of Pancreas
新解决方案 胰岛恢复 保存胰腺
  • 批准号:
    7154824
  • 财政年份:
    2006
  • 资助金额:
    $ 28.51万
  • 项目类别:
Pancreas Transporter Development and Validation
胰腺转运蛋白的开发和验证
  • 批准号:
    6993313
  • 财政年份:
    2005
  • 资助金额:
    $ 28.51万
  • 项目类别:
Pancreas Transporter Development and Validation
胰腺转运蛋白的开发和验证
  • 批准号:
    7123761
  • 财政年份:
    2005
  • 资助金额:
    $ 28.51万
  • 项目类别:
PRESERVATION OF LIVER SLICES BY VITRIFICATION
通过玻璃化保存肝切片
  • 批准号:
    6882959
  • 财政年份:
    2005
  • 资助金额:
    $ 28.51万
  • 项目类别:

相似海外基金

Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
  • 批准号:
    MR/Y019458/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.51万
  • 项目类别:
    Research Grant
Fabrication and Evaluation of Poly(glycerol sebacate) based small diameter vascular graft as a potent substitution for autologous vessels
基于聚(甘油癸二酸酯)的小直径血管移植物作为自体血管有效替代品的制造和评估
  • 批准号:
    2897580
  • 财政年份:
    2023
  • 资助金额:
    $ 28.51万
  • 项目类别:
    Studentship
Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head
自体骨髓抽吸浓缩液治疗股骨头坏死
  • 批准号:
    10658324
  • 财政年份:
    2023
  • 资助金额:
    $ 28.51万
  • 项目类别:
Identifying multimodal biomarkers for autologous serum tears in the treatment of chronic postoperative ocular pain
识别治疗慢性术后眼痛的自体血清泪液的多模式生物标志物
  • 批准号:
    10794761
  • 财政年份:
    2023
  • 资助金额:
    $ 28.51万
  • 项目类别:
SBIR Phase II: An Injectable Protein Matrix to Enhance the Stability of Autologous Fat Grafts
SBIR II 期:可注射蛋白质基质,增强自体脂肪移植物的稳定性
  • 批准号:
    2304430
  • 财政年份:
    2023
  • 资助金额:
    $ 28.51万
  • 项目类别:
    Cooperative Agreement
Application of Autologous Connective Tissue Sheets Created in Patients' Bodies to Pediatric Cardiac Valvuloplasty and Development of Dedicated Molds
患者体内自体结缔组织片在小儿心脏瓣膜成形术中的应用及专用模具的开发
  • 批准号:
    23K15543
  • 财政年份:
    2023
  • 资助金额:
    $ 28.51万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
MICA: Strategy for heart repair in Duchenne Muscular Dystrophy (DMD) using genetically engineered autologous Mesoangioblasts
MICA:利用基因工程自体中成血管细胞修复杜氏肌营养不良症 (DMD) 的心脏的策略
  • 批准号:
    MR/X00466X/1
  • 财政年份:
    2023
  • 资助金额:
    $ 28.51万
  • 项目类别:
    Fellowship
Planning a phase I study of minor salivary gland derived autologous MSCs for prevention of long-term radiation induced xerostomia
计划对小唾液腺来源的自体 MSC 进行 I 期研究,以预防长期辐射引起的口干症
  • 批准号:
    10720234
  • 财政年份:
    2023
  • 资助金额:
    $ 28.51万
  • 项目类别:
SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING
SBIR 第二阶段,主题 429:自体和同种异体细胞治疗制造的新范式
  • 批准号:
    10976161
  • 财政年份:
    2023
  • 资助金额:
    $ 28.51万
  • 项目类别:
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
使用基序新表位肽脉冲的自体树突状细胞对携带带电 HLA-B 结合袋的非小细胞肺癌患者的治疗性疫苗接种策略进行评估。
  • 批准号:
    10721983
  • 财政年份:
    2023
  • 资助金额:
    $ 28.51万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了